NCT02690519View on ClinicalTrials.gov

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

GLPG1837 dose 1

one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks

DRUG

GLPG1837 dose 2

one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks

Trial Locations (5)

Unknown

University Hospital Antwerp, Antwerp

University Hospital Ghent, Ghent

University Hospitals Leuven, Leuven

AMC, Amsterdam

UMC Utrecht, Utrecht

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY